Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES SJ IN SALE OF LINKON
Mandate

VINGE ADVISES SJ IN SALE OF LINKON

December 31, 2014

Vinge assists SJ AB in connection with its sale of 75% of the shares in Linkon AB to SilverRail. SJ retains a 25% interest in the company. Linkon develops and provides advanced ticket- and payment systems for the travel industry, with a focus on rail transportation, and has under SJ’s ownership developed on the Nordic market. SilverRail is a growth oriented company with extensive experience within the railway sector, with presence on the European market e.g. in the UK, Germany and Italy.

Vinge’s team consisted of among others responsible partner Eva Fredriksson and project manager Peter Sundgren as well as associates Louise Berkelius, Charlotta Järnstedt, Filip Brosset, partner Marcus Glader and associate Emil Fahlén-Godö.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024